A seminar series titled "The Yale-New Haven Biotechnology Enterprise Forum" will be held on campus beginning with a talk on Tuesday, Oct. 28.
The five monthly talks, sponsored by The Biotech Committee of Greater New Haven and Yale's Office
of Cooperative Research, will cover the commercial development of biotechnology and are geared toward entrepreneurs and university scientists. All talks will be 4:30-6:30 p.m. at different locations. The series is open to the public free of charge.
The first speaker will be Reid Adler, patent counselor with the Washington, D.C., firm of Morgan, Lewis & Bockius LLP, where he is a partner in the intellectual property/patent practice group. He will speak on "Patent Opportunities for Genomic Inventions." in the Jane Ellen Hope Conference Rm. 216, enter through the Sterling Hall of Medicine, 333 Cedar St.
Mr. Adler is a former director of the Office of Technology Transfer at the National Institutes of Health (NIH), where he was responsible for the management of federal technology transfer activities, including patenting, licensing, and review of Cooperative Research and Development agreements. While at the NIH, he developed policy options for the patenting and licensing of human gene sequences, and coordinated development of the Uniform Biological Materials Transfer Agreement to facilitate the exchange of biomedical research materials between academic institutions.
Other speakers, their topics and the locations of their talks follow: Dec. 2 -- Susan U. Raymond, director of policy programs at the New York Academy of Sciences, "The Role of Universities in Economic Growth," Bass Hall, Bass Center for Molecular and Structural Biology, 266 Whitney Ave.; Jan. 27 -- Mark Edwards, managing partner at Recombinant Capital, a San Francisco-based consulting firm specializing in biotechnology alliances and capitalization, "Trends in Biotechnology Financing," Horchow Hall, School of Management, 135 Prospect St.; March 3 -- Jonathan Gorham, managing partner of Gorham Associates, "University-Based Technology Incubators and Venture Funds." Bass
Hall; April 7 -- Gualberto Ruaño, cofounder and chief executive officer of Genaissance, a New Haven-based biotechnology company focused on pharmacogenomics, "Genomic Strategies and Drug Discovery," Hope Conference Room, enter through 333 Cedar St.
The Biotech Committee is a partnership of the City
of New Haven and The Greater New Haven Chamber of Commerce whose goal is to promote the growth of biotechnology and health-related industry in the region. Membership includes representatives from Yale and other higher-education institutions in the New Haven region as well as business leaders.
Yale's Office of Cooperative Research pursues the
formation of new business ventures with licensing patents and copyrights as its principal development strategies. It also works with other Yale groups on contracting research with the private sector and developing broad technology-based corporate relations.